Home/Biosimilar Atlas/Aflibercept/Afiveg / Mynzepli

Afiveg / Mynzepli

Aflibercept biosimilar developed by Alvotech, development code AVT06. Reference product Eylea.

Brands by market: Afiveg (EU, Stada); Mynzepli (EU, Advanz) · Commercial partner or holder: Stada (EU); Advanz Pharma (EU) · Company profile
FDANot listed
EMAAug 2025authorised
MHRALicenseddate not shown
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 2 of 7 markets
Connections
AfliberceptmoleculeAlvotechdeveloper2 of 7markets1trial behind it4other products, same developer8rival developers in its markets

About Afiveg / Mynzepli

Alvotech's aflibercept was approved in Europe in August 2025 under two names: Afiveg through Stada and Mynzepli through Advanz. As with all Alvotech products it is sold by partners rather than by Alvotech itself. It has not yet been filed in the United States.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union · Afiveg

European Medicines Agency and European CommissionApproved
Brand
Afiveg
Holder or applicant
STADA Arzneimittel AG
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006761
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
EMA

European Union · Mynzepli

European Medicines Agency and European CommissionApproved
Brand
Mynzepli
Holder or applicant
Advanz Pharma Limited
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006438
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA

United Kingdom · Mynzepli

Medicines and Healthcare products Regulatory AgencyApproved
Brand
Mynzepli
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
40 mg/mL vial and syringe
Source
S023 (MHRA Products) · checked Sep 2026
PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Not listed by CDSCO.

EDE

United Arab Emirates

Not listed by EDE.

Trials behind this product

Comparative trials on ClinicalTrials.gov matched to Afiveg / Mynzepli by development code, brand or developer. Registry data, sponsor-entered.

CandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionRegistry record
AVT06AlvotechEyleaPhase 3Comparative efficacyCompletedJun 2022Nov 2023NCT05155293

Other developers in the same markets

Where Afiveg / Mynzepli holds an approval, these are the other aflibercept biosimilars approved in that market.

MarketRivalsDevelopers (product)
EMA8Alteogen (Eyluxvi), Amgen (Pavblu), Biocon Biologics (Yesafili), Celltrion (Eydenzelt), Formycon (Ahzantive / Baiama), Sam Chun Dang Pharm (Eiyzey / Vgenfli), Samsung Bioepis (Opuviz), Sandoz (Enzeevu / Afqlir)
MHRA7Amgen (Pavblu), Biocon Biologics (Yesafili), Celltrion (Eydenzelt), Formycon (Ahzantive / Baiama), Sam Chun Dang Pharm (Eiyzey / Vgenfli), Samsung Bioepis (Opuviz), Sandoz (Enzeevu / Afqlir)

Same developer, other molecules

Other biosimilars in the Atlas developed by Alvotech: Gobivaz / Gotenfia, Selarsdi / Uzpruvo / Usgena, Simlandi / Hukyndra / Libmyris, Zvogra / Kefdensis / Xbonzy / Acvybra.

Chronology

Sources

All aflibercept biosimilars

Planning aflibercept biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.